#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	12602	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2055	603.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1416	1416	C	722	C,G	705,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23332	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3506	659.3	0	.	n	.	0	T695C	SNP	695	695	T	971	971	C	716	C,T	706,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23332	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3506	659.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1613	1613	A	760	A,G	744,4	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23332	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3506	659.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2247	2247	C	754	C,A,G	728,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23332	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3506	659.3	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2873	2873	T	714	T,C	698,9	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23332	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3506	659.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2321	2321	A	719	A	702	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1796	folP	852	852	100.0	folP.l6.c4.ctg.1	1470	120.6	1	SNP	p	R228S	1	.	.	682	684	AGC	986	988	AGC	140;141;141	A;G;C	136;138;136	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4742	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3436	137.1	1	SNP	p	S91F	0	.	.	271	273	TCC	617	619	TCC	192;194;196	T;C,T;C,A	187;190,3;191,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4742	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3436	137.1	1	SNP	p	D95G	0	.	.	283	285	GAC	629	631	GAC	190;189;189	G;A,G;C	187;181,3;186	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4742	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3436	137.1	1	SNP	p	D95N	0	.	.	283	285	GAC	629	631	GAC	190;189;189	G;A,G;C	187;181,3;186	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	531	1330	mtrR	633	633	97.95	mtrR.l15.c17.ctg.1	1299	101.2	0	.	p	.	0	C66trunc	TRUNC	196	196	T	498	498	T	148	T	147	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	531	1330	mtrR	633	633	97.95	mtrR.l15.c17.ctg.1	1299	101.2	0	.	p	.	0	D79N	NONSYN	235	237	GAT	537	539	AAT	153;154;156	A,G;A;T	151,2;153;155	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	531	1330	mtrR	633	633	97.95	mtrR.l15.c17.ctg.1	1299	101.2	0	.	p	.	0	G83E	NONSYN	247	249	GGT	549	551	GAA	153;153;152	G;A,G;A,T	151;149,2;147,2	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	531	1330	mtrR	633	633	97.95	mtrR.l15.c17.ctg.1	1299	101.2	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	615	617	CAC	143;143;142	C,T;A;C	137,2;134;137	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	531	1330	mtrR	633	633	97.95	mtrR.l15.c17.ctg.1	1299	101.2	0	.	p	.	0	A134T	NONSYN	400	402	GCA	702	704	ACA	173;173;171	A;C,T;A	165;165,1;166	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	531	1330	mtrR	633	633	97.95	mtrR.l15.c17.ctg.1	1299	101.2	1	SNP	p	G45D	0	.	.	133	135	GGC	435	437	GGC	177;172;170	G;G;C	174;167;168	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	14	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	354	2.8	0	.	n	.	0	A197.	DEL	197	197	A	238	238	A	2	A	2	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4130	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3023	135.5	1	SNP	p	D86N	0	.	.	256	258	GAC	641	643	GAC	172;174;175	G;A;C	170;169;172	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4130	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3023	135.5	1	SNP	p	S87I	0	.	.	259	261	AGT	644	646	AGT	175;175;177	A,C;G;T,C,G	173,1;173;173,1,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4130	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3023	135.5	1	SNP	p	S87R	0	.	.	259	261	AGT	644	646	AGT	175;175;177	A,C;G;T,C,G	173,1;173;173,1,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4130	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3023	135.5	1	SNP	p	S87W	0	.	.	259	261	AGT	644	646	AGT	175;175;177	A,C;G;T,C,G	173,1;173;173,1,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4130	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3023	135.5	1	SNP	p	S88P	0	.	.	262	264	TCC	647	649	TCC	177;179;179	T;C;C	170;177;177	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3534	parE	1986	1986	100.0	parE.l6.c30.ctg.1	2755	127.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1559	1561	GGC	155;152;155	G;G;C	152;149;151	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3230	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2555	124.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1472	1474	GCA	178;179;183	G,T;C,T,A;A	172,1;170,1,1;179	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3230	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2555	124.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1475	1477	ATC	184;183;183	A;T,A;C	181;178,1;181	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3230	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2555	124.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1487	1489	GTG	193;192;193	G;T;G	188;182;186	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3230	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2555	124.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1487	1489	GTG	193;192;193	G;T;G	188;182;186	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3230	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2555	124.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1991	1993	ACC	144;141;139	A;C;C	136;138;136	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3230	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2555	124.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2045	2047	GCG	153;154;152	G,A;C,G;G	144,1;131,3;141	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3230	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2555	124.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2045	2047	GCG	153;154;152	G,A;C,G;G	144,1;131,3;141	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3230	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2555	124.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2168	2170	GGC	114;112;110	G,A;G;C	109,2;108;109	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3230	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2555	124.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2177	2179	GGC	112;112;109	G;G;C	109;108;108	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3230	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2555	124.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2195	2197	CCG	85;85;87	C;C,G;G	83;82,1;81	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	4978	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3049	162.0	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1634	1636	CTG	157;159;158	C;T,C;G	152;153,1;153	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2046	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1742	115.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	579	579	C	139	C,G	133,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2248	porB1b	1035	1035	95.82	porB1b.l15.c30.ctg.1	1362	159.9	0	.	p	.	0	E48G	NONSYN	142	144	GAA	331	333	GGA	184;180;181	G;G;A	181;178;178	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2248	porB1b	1035	1035	95.82	porB1b.l15.c30.ctg.1	1362	159.9	0	.	p	.	0	F135L	NONSYN	403	405	TTT	592	594	CTT	163;164;163	C,G;T;T,G	159,2;160;159,2	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2248	porB1b	1035	1035	95.82	porB1b.l15.c30.ctg.1	1362	159.9	0	.	p	.	0	R143G	NONSYN	427	429	AGA	616	618	GGA	164;159;160	G,A;G,A;A	162,1;158,1;154	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2248	porB1b	1035	1035	95.82	porB1b.l15.c30.ctg.1	1362	159.9	0	.	p	.	0	D171G	NONSYN	511	513	GAT	700	702	GGT	160;163;163	G;G,A;T,C	153;158,2;156,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2248	porB1b	1035	1035	95.82	porB1b.l15.c30.ctg.1	1362	159.9	0	.	p	.	0	G189S	NONSYN	565	567	GGC	754	756	AGC	162;159;157	A,G;G,A;C,T	154,1;151,2;150,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2248	porB1b	1035	1035	95.82	porB1b.l15.c30.ctg.1	1362	159.9	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	820	820	T	147	T	142	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2248	porB1b	1035	1035	95.82	porB1b.l15.c30.ctg.1	1362	159.9	1	SNP	p	G120K	0	.	.	358	360	GGT	547	549	GGT	153;151;150	G,A;G,A;T,G	148,1;145,1;137,2	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2248	porB1b	1035	1035	95.82	porB1b.l15.c30.ctg.1	1362	159.9	1	SNP	p	A121D	0	.	.	361	363	GCC	550	552	GCC	149;149;154	G,A;C,A;C,A	141,1;144,1;148,1	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2248	porB1b	1035	1035	95.82	porB1b.l15.c30.ctg.1	1362	159.9	1	SNP	p	A121N	0	.	.	361	363	GCC	550	552	GCC	149;149;154	G,A;C,A;C,A	141,1;144,1;148,1	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8748	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4850	178.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2013	2015	AAT	188;191;191	A,C;A;T	184,1;188;187	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	972	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	949	101.2	1	SNP	p	V57M	1	.	.	169	171	ATG	504	506	ATG	177;176;180	A;T;G	174;173;175	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
